Clinical trials: Malignant Neoplasm of Prostate
Castration-Sensitive Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
This phase II trial studies how well antiandrogen therapy, abiraterone acetate, and prednisone with or without neutron radiation therapy work in treating patients with prostate cancer.
- Conditions
- Castration-Sensitive Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma
- Trial name
- NCT03649841
- Testing
- Antiandrogen Therapy, Abiraterone Acetate, Prednisone
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Washington
Prostatic Neoplasm, Adenocarcinoma
Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression.
The course and progression of prostate cancer is highly variable, depending on the individual characteristics, the aggressiveness of the disease at the time of diagnosis as well as the ethno-geographic origins of the individuals.
- Conditions
- Prostatic Neoplasm, Adenocarcinoma, Neoplasm Recurrence, Neoplasm Metastasis
- Trial name
- KP-CARAIBES (NCT06046131)
- Testing
- Standard care
- Where
- 2 sites in France, Guadeloupe
- Volunteers
- 3,000 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer
This phase II trial studies how well surgery and radiation therapy work in treating patients with prostate cancer that has come back or spread to other parts of the body.
- Conditions
- Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Oligometastasis
- Trial name
- SOAR (NCT03796767)
- Testing
- Hypofractionated Radiation Therapy, Intensity-Modulated Radiation Therapy, Metastasectomy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Utah
Prostate Cancer
BKM120+Abiraterone Acetate for Metastatic CRPC
This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational drug, in this case an investigational drug combined with standard drug therapy.
- Trial name
- NCT01741753
- Testing
- BKM120, Abiraterone, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Neoplasms, Colorectal Neoplasms
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor…
- Conditions
- Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
- Trial name
- OMNIRAY (NCT07114601)
- Testing
- LY4257496, Standard of Care Anticancer Therapies, LY4257529
- Where
- 33 sites in United States, Canada and 5 more
- Volunteers
- 421 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer, Metastasis
Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients
This will be a confirmatory, prospective, open-label, single-arm, reader-blinded, multi-centre phase 3 study to assess the diagnostic accuracy and safety of Ferrotran®-enhanced MRI in comparison to unenhanced MRI in the detection…
- Conditions
- Prostate Cancer, Metastasis, Prostatectomy
- Trial name
- NCT04261777
- Testing
- Ferrotran® (Ferumoxtran-10)
- Where
- 15 sites in Belgium, Germany and 2 more
- Volunteers
- 172 people
- Sponsor
- Saving Patients' Lives Medical B.V.
Prostate Cancer Metastatic
Androgen Deprivation Therapy (ADT) Versus ADT Plus Prostate Cryotherapy for Metastatic Prostate Cancer (mPCa)
Patients with primary diagnosed metastatic prostate cancer are randomly divided into two groups. One group receive standard of care ADT continually. Another group receive ADT plus prostate cryotherapy.
- Trial name
- NCT03129854
- Testing
- prostate cryotherapy
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Sun Yat-sen University
Prostatic Neoplasms, Castration-Resistant
Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer
The primary objective was to confirm the effect of tasquinimod in delaying disease progression or death as compared with placebo in chemo-naïve patients with metastatic castrate-resistant prostate cancer (mCRPC).
- Trial name
- TasQ003 (NCT02057666)
- Testing
- Tasquinimod
- Where
- 36 sites in China, South Korea and 1 more
- Volunteers
- 146 people
- Sponsor
- Ipsen
Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer
A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors
The purpose of the trial is to evaluate the safety, determine the recommended Phase 2 dose (RP2D), and assess preliminary clinical activity of GEN1044 in patients with solid tumors.
- Conditions
- Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer, Esophageal Cancer, Triple Negative Breast Cancer (TNBC)
- Trial name
- NCT04424641
- Testing
- GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
- Where
- 6 sites in United States, Denmark and 2 more
- Volunteers
- 48 people
- Sponsor
- Genmab
Breast Cancer, Colorectal Cancer
Michigan Genetic Hereditary Testing (MiGHT)
The primary purpose of this study is to compare three interventions, two experimental and one standard of care (usual care), to see if the experimental interventions will increase the likelihood of a participant obtaining…
- Conditions
- Breast Cancer, Colorectal Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- MiGHT (NCT05162846)
- Testing
- Publicly available genetic testing resources, Virtual genetics navigator, Motivational interviewing (MI)
- Where
- United States
- Volunteers
- 793 people, healthy volunteers welcome
- Sponsor
- University of Michigan Rogel Cancer Center
Prostatic Neoplasms
Safety Study of TAK-700 in Subjects With Prostate Cancer.
The purpose of this study is to determine the safety and tolerability of TAK-700 in patients with asymptomatic metastatic, androgen independent prostate cancer.
- Trial name
- TAK-700 (NCT00569153)
- Testing
- TAK-700
- Where
- 19 sites in United States
- Volunteers
- 123 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Malignant Neoplasms of Male Genital Organs, Prostate Cancer
Neoadjuvant Listeria or Daratumumab in Prostate Cancer
The goal of this clinical research study is to learn about biomarker changes in patients who have primary prostate cancer after receiving Darzalex (daratumumab) and then have a prostatectomy (the surgical removal of the prostate)…
- Trial name
- NCT03035357
- Testing
- Daratumumab
- Sponsor
- M.D. Anderson Cancer Center
Prostatic Neoplasm
High Field Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Brachytherapy Implantation
The purpose of this study is to establish the correct scanning parameters for obtaining good quality 3 Tesla (3T) magnetic resonance spectroscopy images (MRSI) of the prostate gland before and after brachytherapy implantation for…
- Trial name
- NCT00126854
- Testing
- Magnetic Resonance Spectroscopy Imaging
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- AHS Cancer Control Alberta
Prostate Cancer
Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine
The purpose of this study is to evaluate clinical and laboratory safety in patients receiving 4 different doses of GVAX® Prostate Cancer Vaccine in order to determine a maximum tolerated dose.
- Trial name
- NCT00140348
- Testing
- Immunotherapy allogeneic GM-CSF secreting cellular vaccine
- Where
- 12 sites in United States
- Volunteers
- 80 people
- Sponsor
- Cell Genesys
Adenocarcinoma of the Prostate
Pilot Study of DRibble Vaccine for Prostate Cancer Patients
This is a pilot study of the DRibble vaccine in patients with advanced prostate cancer.
- Trial name
- DRibble (NCT02234921)
- Testing
- Cyclophosphamide, DRibble Vaccine, HPV Vaccinations
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- UbiVac
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones
This phase II trial studies the effect of Sn-117m-DTPA on bone pain in patients with prostate cancer that has spread to the bones. Sn-117m-DTPA is a radioactive therapeutic agent that localizes to bones when given to patients.
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT04616547
- Testing
- Questionnaire Administration, Tin Sn 117m Pentetate
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Study of SU11248 in Men With Advanced Prostate Cancer
There are nearly 30,000 deaths per year in the United States from prostate cancer, making this a large and important target patient population for new cancer treatments.
- Trial name
- NCT00299741
- Testing
- Sunitinib
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Massachusetts General Hospital
Advanced Malignant Neoplasm, Cervical Squamous Cell Carcinoma
Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations
This pilot trial studies how well nanoparticle albumin-bound rapamycin works in treating patients with cancer that as has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced…
- Conditions
- Advanced Malignant Neoplasm, Cervical Squamous Cell Carcinoma, Endometrial Carcinoma, Malignant Uterine Neoplasm
- Trial name
- NCT02646319
- Testing
- Laboratory Biomarker Analysis, Nanoparticle Albumin-Bound Rapamycin, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
Prostate Cancer, Prostate Neoplasm
Addition of a Focal Boost in External Beam Radiotherapy for Locally Advanced Prostate Cancer by Online Adaptive MR-guided Radiotherapy
The AFFIRM trial tests the safety and clinical feasibility of MR-guided hypofractionated focal boost radiotherapy for patients with locally advanced prostate cancer.
- Trial name
- AFFIRM (NCT05373316)
- Testing
- Ultrahypofractionated MR-guided radiotherapy boost
- Where
- 2 sites in Netherlands
- Volunteers
- 95 people
- Sponsor
- Radboud University Medical Center
Prostate Cancer
Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer
Evaluate the efficacy of Abraxane in first line chemotherapy of patients with hormone refractory metastatic prostate cancer, based on prostate specific antigen (PSA) response
- Trial name
- NCT00284752
- Testing
- Abraxane
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Kaiser Permanente